Skvarka Jan
Insider CIK 1838042 · TRIL President and CEO, Director · ZNTL Director · GLUE Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals, | A Award | 2026-06-16 | 2026-06-18 | 57,100 | — | $0 | 264,254 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2026-06-11 | 2026-06-12 | 25,800 | — | $0 | 25,800 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2025-06-17 | 2025-06-18 | 57,603 | — | $0 | 207,154 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2025-06-13 | 2025-06-16 | 30,700 | — | $0 | 30,700 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | P Buy | 2025-01-31 | 2025-02-04 | 60,000 | $1.72 | $103.2K | 149,551 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2024-06-21 | 2024-06-21 | 41,581 | — | $0 | 89,551 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2024-06-12 | 2024-06-13 | 22,100 | — | $0 | 22,100 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | S Sale | 2023-09-11 | 2023-09-13 | 5,000 | $25.05 | $125.3K | 47,970 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2023-06-16 | 2023-06-16 | 16,364 | — | $0 | 52,970 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2023-06-14 | 2023-06-15 | 20,500 | — | $0 | 20,500 | SEC↗ |
| GLUE Monte Rosa Therapeutics, I | A Award deriv | 2023-03-30 | 2023-03-31 | 41,000 | — | $0 | 41,000 | SEC↗ |
| ZNTL Zentalis Pharmaceuticals, | A Award | 2022-09-09 | 2022-09-12 | 36,606 | — | $0 | 36,606 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | D To issuer deriv | 2021-11-17 | 2021-11-19 | 600,000 | — | $0 | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | D To issuer deriv | 2021-11-17 | 2021-11-19 | 1,162,500 | — | $0 | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | D To issuer deriv | 2021-11-17 | 2021-11-19 | 197,000 | — | $0 | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise deriv | 2021-05-12 | 2021-05-13 | 23,802 | — | $0 | 197,000 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise | 2021-05-12 | 2021-05-13 | 23,802 | $0.31 | $7.4K | 23,802 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | S Sale | 2021-05-12 | 2021-05-13 | 23,802 | $9.24 | $219.9K | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise deriv | 2021-05-11 | 2021-05-13 | 19,198 | — | $0 | 220,802 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise deriv | 2021-05-11 | 2021-05-13 | 87,500 | — | $0 | 1,162,500 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise | 2021-05-11 | 2021-05-13 | 87,500 | $0.45 | $39.4K | 87,500 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise | 2021-05-11 | 2021-05-13 | 19,198 | $0.31 | $6.0K | 106,698 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | S Sale | 2021-05-11 | 2021-05-13 | 106,698 | $9.20 | $981.6K | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise deriv | 2021-01-14 | 2021-01-15 | 19,581 | — | $0 | 1,250,000 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | S Sale | 2021-01-14 | 2021-01-15 | 19,581 | $15.03 | $294.3K | 0 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise | 2021-01-14 | 2021-01-15 | 19,581 | $0.43 | $8.4K | 19,581 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise deriv | 2021-01-13 | 2021-01-15 | 5,419 | — | $0 | 1,269,581 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | M Exercise | 2021-01-13 | 2021-01-15 | 5,419 | $0.42 | $2.3K | 5,419 | SEC↗ |
| TRIL Trillium Therapeutics Inc. | S Sale | 2021-01-13 | 2021-01-15 | 5,419 | $15.04 | $81.5K | 0 | SEC↗ |